Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects

Aim of this study is to enhance the knowledge of myogenic tone alterations in hypertensive patients and to better understand the mechanisms controlling the myogenic tone. Evaluations will be performed through ex vivo studies of peripheral arterioles in human adipose tissue from lumbar muscle, isolated from biopsies. This will allow investigators to evaluate the myogenic function in response to progressive blood pressure increases, in order to correlate myogenic function to arterial hypertension and to the molecular mechanisms already identified in the preclinical models.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

30 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS Neuromed

Pozzilli, Isernia, 86077, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Males or females between 30 and 70 years of age
Hypertensive patients: Patients with a previous diagnosis of hypertension
Normotensive patients: subjects without story of hypertension
Written informed consent

Exclusion criteria

Severe hypertension (eg, systolic >180 mm Hg, diastolic >110 mm Hg)
Manifested or suspected secondary hypertension (coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, pheochromocytoma)
History of cardiac complications (previous acute myocardial infarction (AMI), unstabile angina, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass grafting (CABG), congestive heart failure (NYHA II-IV))
Diabetes mellitus
Renal pathologies (creatinine clearance < 30 ml/min)
Severe hepatic dysfunction

Treatment and study plan

Primary outcomes

Myogenic tone measured by micromyographic technique to evaluate small-artery morphology.

Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Neuromed IRCCS

Other

Registry information

Important dates

Study start: 2015
Primary completion: 2020
Study completion: 2020
First posted: Dec 9, 2014
Registry last updated: Jan 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed